{
    "pmcid": "8928829",
    "qa_pairs": {
        "How does NIH-CoVnb-112 achieve broad neutralization against multiple SARS-CoV-2 variants?": [
            "By binding conserved regions of the RBD that are less prone to mutation",
            "By targeting the N-terminal domain of the spike protein",
            "By inducing conformational changes in the spike protein",
            "By enhancing the host immune response through Fc receptor binding"
        ],
        "What is the advantage of delivering NIH-CoVnb-112 via nebulization?": [
            "It targets respiratory infections directly at the site of viral entry",
            "It enhances systemic circulation of the nanobody",
            "It allows for oral administration of the nanobody",
            "It increases the half-life of the nanobody in the bloodstream"
        ],
        "What is the primary site for ACE2 interaction on the SARS-CoV-2 spike protein?": [
            "Receptor-binding motif (RBM)",
            "N-terminal domain (NTD)",
            "S2 subunit",
            "Fusion peptide"
        ],
        "What structural feature of NIH-CoVnb-112 is crucial for its stable binding to the RBD?": [
            "Complementarity-determining region 3 (CDR3)",
            "Variable light chain (VL) domain",
            "Constant heavy chain (CH) domain",
            "Fc region"
        ],
        "Which mutations are commonly found in variants of concern like Alpha, Beta, Gamma, and Delta?": [
            "E484K, N501Y, and K417N/T",
            "D614G, P681R, and L452R",
            "Q677H, T478K, and A222V",
            "H69/V70 deletion, Y144 deletion, and S477N"
        ]
    }
}